Hypofractionated Radiotherapy for Lung Cancer
The purpose of this trial is to pilot reducing the duration of radiation treatment for lung cancer patients from 6 to 5 weeks using tomotherapy. Specific patient doses will be based on tumor volume being treated. Modeling has shown that increased biologically effective dose (BED) to tumors can be achieved by shortening the radiation delivery schedule and increasing the dose per fraction. This requires decreasing the total dose to hold lung toxicity constant at each dose per fraction level. This is a major paradigm shift in the treatment in this disease and is projected to result in significant improvements in patient outcome as well as a substantial cost savings.
Checked against the public recordLast updated Dec 13, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Prevention
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- University of Wisconsin, Madison
- Interventions being studied
- Radiation: radiation therapy (radiotherapy)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Thoracic neoplasm requiring at lest 60 Gy conventional radiotherapy Exclusion Criteria: * Prior bleomycin or gemcitabine chemotherapy * Prior thoracic radiotherapy
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Wisconsin Hospital and ClinicsMadison, Wisconsin
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 13, 2019. Always confirm current availability with the study team.